Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-4359 alone and with checkpoint blockade in advanced solid tumors
2023-504506-11-00Phase 2Authorised
- Sponsor
- Moderna Inc
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 2, open-label trial of mRNA-4359 in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 5 more (6 arms), sponsored by Moderna Inc. Planned start Oct 2023; status: authorised.
02
Drugs
mRNA-4359
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)non-muscle-invasive bladder cancer (NMIBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-504506-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504506-11-00.